Farzad Rahmani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Farzad Rahmani has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Pegah Safavi
Department of Medical Radiation, Islamic Azad University, Science and Research Branch, Tehran, Iran
2 shared publications- Abozar Ghorbani
Nuclear Agriculture Research School, Nuclear Science and Technology Research Institute (NSTRI), Karaj, Iran
1 shared publication - Alireza Pasdar
Department of Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran
1 shared publication Amir Avan
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publicationAmirhosein Jafarian
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publicationAzam Rastgar Moghadam
Basic Medical Sciences Institute, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication
Latest Publications
- Open Access
- 29 June 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
A Prospective to Regulatory Role of miRNAs on Wnt/β-catenin Signaling and Its Crosstalk to the Other Cellular Pathways in Tumorigenesis of Glioblastoma by a Systems Biology Approach
Background: The Wnt plays a crucial role in the initiation, progression, and spread of glioblastoma (GBM). Recently, microRNAs (miRNAs) have been demonstrated to be key players in controlling cell growth and tumor formation. Objectives: The present study offers the latest insight into miRNAs that influence the Wnt pathway and their interaction with protein-coding genes. Methods: Previous studies on the regulatory function of miRNAs targeting the Wnt/catenin pathway were reviewed, and all miRNA-targeted genes were found in the miRDB database. Protein-protein interactions (PPIs) of miRNA-targeted genes were investigated using String and Cytoscape software, and hub proteins were examined. Gene-subnetwork Gene Ontology (GO) analysis was performed. Results: At first, 13 downregulated and 25 upregulated miRNAs targeting the Wnt pathway were obtained, each targeting 1,685 and 1,313 genes, respectively; 12 and 15 hub proteins were found in dysregulated miRNA-targeted genes, which interacted with most genes. The PPI network analysis and subnetwork GO analysis showed these proteins cross-talk with many other proteins that have key roles in the pathways that cause proliferation and malignancy in cells. Conclusions: Hub proteins are oncogenic proteins that increase gene replication and suppress apoptotic pathways, or tumor suppressors that prevent cancer. By focusing on hub proteins alone or as part of a multi-target approach, it is possible to treat GBM tumors successfully.
- 29 June 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
Open AccessA Prospective to Regulatory Role of miRNAs on Wnt/β-catenin Signaling and Its Crosstalk to the Other Cellular Pathways in Tumorigenesis of Glioblastoma by a Systems Biology Approach
Background: The Wnt plays a crucial role in the initiation, progression, and spread of glioblastoma (GBM). Recently, microRNAs (miRNAs) have been demonstrated to be key players in controlling cell growth and tumor formation. Objectives: The present study offers the latest insight into miRNAs that influence the Wnt pathway and their interaction with protein-coding genes. Methods: Previous studies on the regulatory function of miRNAs targeting the Wnt/catenin pathway were reviewed, and all miRNA-targeted genes were found in the miRDB database. Protein-protein interactions (PPIs) of miRNA-targeted genes were investigated using String and Cytoscape software, and hub proteins were examined. Gene-subnetwork Gene Ontology (GO) analysis was performed. Results: At first, 13 downregulated and 25 upregulated miRNAs targeting the Wnt pathway were obtained, each targeting 1,685 and 1,313 genes, respectively; 12 and 15 hub proteins were found in dysregulated miRNA-targeted genes, which interacted with most genes. The PPI network analysis and subnetwork GO analysis showed these proteins cross-talk with many other proteins that have key roles in the pathways that cause proliferation and malignancy in cells. Conclusions: Hub proteins are oncogenic proteins that increase gene replication and suppress apoptotic pathways, or tumor suppressors that prevent cancer. By focusing on hub proteins alone or as part of a multi-target approach, it is possible to treat GBM tumors successfully.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (5) , 352-361
Interplay between LncRNA/miRNA and TGF-β Signaling in the Tumorigenesis of Gynecological Cancer
Gynecologic cancers are among the most common malignancies with aggressive features and poor prognosis. Tumorigenesis in gynecologic cancers is a complicated process that is influenced by multiple factors, including genetic mutations that activate various oncogenic signaling pathways, including the TGF-β pathway. Aberrant activation of TGF-β signaling is correlated with tumor recurrence and metastasis. It has been shown that non-coding RNAs (ncRNAs) have crucial effects on cancer cell proliferation, migration, and metastasis. Upregulation of various ncRNAs, including long non-coding RNAs (lncRNA) and microRNAs (miRNAs), has been reported in several tumors, like cervical, ovarian, and endometrial cancers, but their cellular mechanisms remain to be investigated. Thus, recognizing the role of ncRNAs in regulating the TGF-β pathway may provide novel strategies for better treatment of cancer patients. The present study summarizes recent findings on the role of ncRNAs in regulating the TGF-β signaling involved in tumor progression and metastasis in gynecologic cancers.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (5) , 352-361
Interplay between LncRNA/miRNA and TGF-β Signaling in the Tumorigenesis of Gynecological Cancer
Gynecologic cancers are among the most common malignancies with aggressive features and poor prognosis. Tumorigenesis in gynecologic cancers is a complicated process that is influenced by multiple factors, including genetic mutations that activate various oncogenic signaling pathways, including the TGF-β pathway. Aberrant activation of TGF-β signaling is correlated with tumor recurrence and metastasis. It has been shown that non-coding RNAs (ncRNAs) have crucial effects on cancer cell proliferation, migration, and metastasis. Upregulation of various ncRNAs, including long non-coding RNAs (lncRNA) and microRNAs (miRNAs), has been reported in several tumors, like cervical, ovarian, and endometrial cancers, but their cellular mechanisms remain to be investigated. Thus, recognizing the role of ncRNAs in regulating the TGF-β pathway may provide novel strategies for better treatment of cancer patients. The present study summarizes recent findings on the role of ncRNAs in regulating the TGF-β signaling involved in tumor progression and metastasis in gynecologic cancers.
- 1 November 2023
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 19 (4) , 358-362
Association of a Genetic Variant in Chromosome 9p21 with Increased Risk of Developing Cervical Cancer
Background: Cervical cancer is one of the most prevalent gynecologic cancers associated with high morbidity and mortality worldwide. There is mounting evidence indicating an association between the 9p21 locus genetic variants with susceptibility to various human malignancies. In this current study, we aimed to evaluate the potential relationship between the rs1333049 genetic variant in chromosome 9p21 and the risk of cervical carcinogenesis. Methods: The possible correlation between rs1333049 polymorphism and susceptibility to cervical cancer was investigated in 221 patients with or without cancer. DNAs were isolated and genotyped using a TaqMan-based real-time RT-PCR method. Results: The rs1333049 genetic variant was found to be correlated with an elevated risk of cervical neoplasia using recessive and additive genetic models (p < 0.001). Conclusion: Our findings indicated that the CDKN2A/B genetic variant (rs1333049) was significantly associated with an elevated risk of cancer, suggesting its potential as a novel predictive marker for cervical carcinogenesis.
- 1 November 2023
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 19 (4) , 358-362
Association of a Genetic Variant in Chromosome 9p21 with Increased Risk of Developing Cervical Cancer
Background: Cervical cancer is one of the most prevalent gynecologic cancers associated with high morbidity and mortality worldwide. There is mounting evidence indicating an association between the 9p21 locus genetic variants with susceptibility to various human malignancies. In this current study, we aimed to evaluate the potential relationship between the rs1333049 genetic variant in chromosome 9p21 and the risk of cervical carcinogenesis. Methods: The possible correlation between rs1333049 polymorphism and susceptibility to cervical cancer was investigated in 221 patients with or without cancer. DNAs were isolated and genotyped using a TaqMan-based real-time RT-PCR method. Results: The rs1333049 genetic variant was found to be correlated with an elevated risk of cervical neoplasia using recessive and additive genetic models (p < 0.001). Conclusion: Our findings indicated that the CDKN2A/B genetic variant (rs1333049) was significantly associated with an elevated risk of cancer, suggesting its potential as a novel predictive marker for cervical carcinogenesis.